Press
·
News
P+P advised Wellington Partners on sale of Symetis to Boston Scientific
Boston Scientific Corporation acquired Symetis SA from Wellington Partners and other shareholders. The purchase price was USD 435 million and was paid in cash.
Symetis SA is a privately held structural heart disease company in Switzerland specializing in the manufacture of minimally invasive transcatheter aortic valve implantation (TAVI) systems.
The acquisition expands Boston Scientific's Structural Heart portfolio and broadens the range of treatments for heart valve disease patients.
P+P Pöllath + Partners advised Wellington Partners on the transaction with the following Munich-based team:
- Dr. Michael Inhester (partner, lead, M&A, private equity)
- Adalbert Makos (senior associate, M&A, private equity)
P+P Pöllath + Partners previously advised Middle Peak Medical GmbH on its acquisition by Symetis.
